Novabay Pharmaceuticals Inc (NBY)

$0.62

-0.01

(-1.59%)▲

Live

Performance

  • $0.61
    $0.67
    $0.62
    downward going graph

    1.61%

    Downside

    Day's Volatility :8.53%

    Upside

    7.03%

    downward going graph
  • $0.36
    $13.20
    $0.62
    downward going graph

    41.76%

    Downside

    52 Weeks Volatility :97.26%

    Upside

    95.3%

    downward going graph

Returns

PeriodNovabay Pharmaceuticals IncIndex (Russel 2000)
3 Months
-69.72%
0.0%
6 Months
-75.18%
0.0%
1 Year
-94.86%
0.0%
3 Years
-99.91%
-23.0%

Highlights

Market Capitalization
2.9M
Book Value
-$0.46
Earnings Per Share (EPS)
-76.04
PEG Ratio
0.0
Wall Street Target Price
7.3
Profit Margin
-76.81%
Operating Margin TTM
-43.88%
Return On Assets TTM
-32.8%
Return On Equity TTM
-282.96%
Revenue TTM
13.9M
Revenue Per Share TTM
25.34
Quarterly Revenue Growth YOY
-32.1%
Gross Profit TTM
5.6M
EBITDA
-5.0M
Diluted Eps TTM
-76.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.41
EPS Estimate Next Year
-0.84
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-0.7

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Novabay Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
4
5
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1077.42%

Current $0.62
Target $7.30

Company Financials

FY18Y/Y Change
Revenue
12.5M
↓ 31.39%
Net Income
-6.5M
↓ 11.59%
Net Profit Margin
-52.33%
↓ 11.72%
FY19Y/Y Change
Revenue
6.6M
↓ 47.24%
Net Income
-10.5M
↑ 60.23%
Net Profit Margin
-158.92%
↓ 106.59%
FY20Y/Y Change
Revenue
9.9M
↑ 50.54%
Net Income
-11.0M
↑ 5.26%
Net Profit Margin
-111.12%
↑ 47.8%
FY21Y/Y Change
Revenue
8.4M
↓ 15.23%
Net Income
-6.6M
↓ 40.58%
Net Profit Margin
-77.89%
↑ 33.23%
FY22Y/Y Change
Revenue
14.4M
↑ 71.05%
Net Income
-16.3M
↑ 147.98%
Net Profit Margin
-112.92%
↓ 35.03%
FY23Y/Y Change
Revenue
14.7M
↑ 2.24%
Net Income
-9.6M
↓ 40.73%
Net Profit Margin
-65.46%
↑ 47.46%
Q1 FY23Q/Q Change
Revenue
3.1M
↓ 14.25%
Net Income
-1.7M
↓ 78.81%
Net Profit Margin
-55.67%
↑ 169.58%
Q2 FY23Q/Q Change
Revenue
4.6M
↑ 47.57%
Net Income
-4.0M
↑ 131.86%
Net Profit Margin
-87.46%
↓ 31.79%
Q3 FY23Q/Q Change
Revenue
3.3M
↓ 29.39%
Net Income
-1.8M
↓ 56.42%
Net Profit Margin
-53.98%
↑ 33.48%
Q4 FY23Q/Q Change
Revenue
3.7M
↑ 14.5%
Net Income
-4.1M
↑ 133.81%
Net Profit Margin
-110.22%
↓ 56.24%
Q1 FY24Q/Q Change
Revenue
2.6M
↓ 29.41%
Net Income
-3.2M
↓ 21.76%
Net Profit Margin
-122.16%
↓ 11.94%
Q2 FY24Q/Q Change
Revenue
2.4M
↓ 8.78%
Net Income
-1.6M
↓ 50.68%
Net Profit Margin
-66.04%
↑ 56.12%
FY18Y/Y Change
Total Assets
9.4M
↓ 7.12%
Total Liabilities
4.4M
↓ 41.12%
FY19Y/Y Change
Total Assets
11.2M
↑ 19.86%
Total Liabilities
10.2M
↑ 132.52%
FY20Y/Y Change
Total Assets
15.2M
↑ 35.81%
Total Liabilities
2.9M
↓ 71.5%
FY21Y/Y Change
Total Assets
24.0M
↑ 57.36%
Total Liabilities
13.8M
↑ 372.84%
FY22Y/Y Change
Total Assets
16.4M
↓ 31.61%
Total Liabilities
5.8M
↓ 57.67%
FY23Y/Y Change
Total Assets
9.0M
↓ 44.91%
Total Liabilities
5.7M
↓ 2.14%
Q1 FY23Q/Q Change
Total Assets
14.8M
↓ 9.6%
Total Liabilities
5.9M
↑ 1.54%
Q2 FY23Q/Q Change
Total Assets
16.0M
↑ 7.98%
Total Liabilities
7.4M
↑ 25.44%
Q3 FY23Q/Q Change
Total Assets
12.9M
↓ 19.72%
Total Liabilities
5.8M
↓ 21.89%
Q4 FY23Q/Q Change
Total Assets
9.0M
↓ 29.71%
Total Liabilities
5.7M
↓ 1.63%
Q1 FY24Q/Q Change
Total Assets
5.4M
↓ 40.7%
Total Liabilities
5.2M
↓ 9.14%
Q2 FY24Q/Q Change
Total Assets
3.9M
↓ 26.73%
Total Liabilities
4.5M
↓ 12.6%
FY18Y/Y Change
Operating Cash Flow
-5.6M
↓ 11.2%
Investing Cash Flow
-44.0K
↓ 81.97%
Financing Cash Flow
5.6M
↑ 2684.58%
FY19Y/Y Change
Operating Cash Flow
-7.9M
↑ 42.4%
Investing Cash Flow
-19.0K
↓ 56.82%
Financing Cash Flow
11.7M
↑ 109.08%
FY20Y/Y Change
Operating Cash Flow
-4.7M
↓ 40.46%
Investing Cash Flow
-26.0K
↑ 36.84%
Financing Cash Flow
9.8M
↓ 16.58%
FY21Y/Y Change
Operating Cash Flow
-9.2M
↑ 94.7%
Investing Cash Flow
-12.0M
↑ 46226.92%
Financing Cash Flow
16.8M
↑ 71.98%
FY22Y/Y Change
Operating Cash Flow
-6.7M
↓ 27.61%
Investing Cash Flow
-112.0K
↓ 99.07%
Financing Cash Flow
4.6M
↓ 72.4%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.6M
↑ 33.25%
Investing Cash Flow
-13.0K
↓ 88.39%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.8M
↑ 14.4%
Investing Cash Flow
-15.0K
↑ 15.38%
Financing Cash Flow
2.5M
-

Technicals Summary

Sell

Neutral

Buy

Novabay Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Novabay Pharmaceuticals Inc
Novabay Pharmaceuticals Inc
-15.69%
-75.18%
-94.86%
-99.91%
-99.91%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Novabay Pharmaceuticals Inc
Novabay Pharmaceuticals Inc
NA
NA
0.0
-1.41
-2.83
-0.33
NA
-0.46
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Novabay Pharmaceuticals Inc
Novabay Pharmaceuticals Inc
Buy
$2.9M
-99.91%
NA
-76.81%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Novabay Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 3.72M → 2.4M (in $), with an average decrease of 19.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -4.10M → -1.58M (in $), with an average increase of 65.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 177.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.7%

Company Information

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Organization
Novabay Pharmaceuticals Inc
Employees
24
CEO
Mr. Justin M. Hall Esq.
Industry
Health Technology

Discover More

FAQs